Merck KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by ...

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its ... the mid-point and sales around the lower half of ...

Bernstein has recently initiated Merck & Co Inc (MRK) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on March 11, 2024, Societe Generale had reduced the ...

Shares of Merck & Co. Inc. MRK inched 0.44% higher to $101.17 Thursday, on what proved to be an all-around mixed trading ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

"We're excited to achieve the first milestone of our collaboration with Merck and continue our work to improve biologic ...

On Tuesday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $101.65 which represents a decrease of $-0.22 or -0.22% from the prior close of $101.87. The stock opened at $101.36 and touched ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...